Ilosone 200/Ilosone DS

Upper & lower resp tract, skin & soft tissue infections of mild to moderate severity. Ilosone DS Primary syphilis in penicillin-allergic patients; erythrasma; intestinal amebiasis; pertussis; conjunctivitis of the newborn, pneumonia of infancy, urogenital infections during pregnancy; uncomplicated urethral endocervical or rectal infections.

Ilosone 200 Childn 6-12 yr 5-7.5 mL bid-tid, 2-6 yr 2.5-5 mL bid-tid, 1-2 yr 1.25-2.5 mL bid-tid. Ilosone DS General: Adult 250 mg every 6 hr, may be increased up to ≥4 g/day. Childn 30-50 mg/kg/day in divided doses. May be doubled in severe infections. Specific: Streptococcal pharyngitis & tonsillitis Usual dose: 20-50 mg/kg/day in divided doses. Patient weighing ≥36 kg 1,000 mg total daily dose, 25-36 kg 750 mg total daily dose, 18-25 kg 500 mg total daily dose, 11-18 kg 375 mg total daily dose, ≤10 kg 250 mg total daily dose. Continuous prophylaxis of streptococcal infections in patient w/ history of rheumatic heart disease 250 mg bid. Prophylaxis against bacterial endocarditis in penicillin-allergic patient w/ congenital heart disease/rheumatic/other acquired valvular heart disease when undergoing dental/surgery procedure of the upper resp tract Adult 1 g orally 1 hr pre-op, then 500 mg orally 6 hr post-op. Childn 20 mg/kg orally 1 hr pre-op, then 10 mg/kg orally 6 hr post-op. Primary syphilis 20 g in divided doses over a period of 10 days. Dysenteric amebiasis Adult 250 mg qid for 10-14 days. Childn 30-50 mg/kg/day in divided doses for 10-14 days. Pertussis 40-50 mg/kg/day in divided doses for 5-14 days. Legionnaire's disease 1-4 g daily in divided doses. Conjunctivitis of the newborn 50 mg/kg/day in 4 divided doses for at least 2 wk. Pneumonia of infancy 50 mg/kg/day in 4 divided doses for at least 3 wk. Urogenital infections during pregnancy 500 mg qid for at least 7 days. For women who cannot tolerate this regimen, reduce dose to 250 mg qid for at least 14 days. Uncomplicated urethral, endocervical, or rectal infections 500 mg qid for at least 7 days.

Ilosone 200 May be taken with or without food. Ilosone DS Should be taken on an empty stomach: Best taken 1 hr before or 2 hr after meals. May be taken w/ meals to reduce GI discomfort.

Hypersensitivity. Patients taking terfenadine, astemizole, pimozide, or cisapride. Ilosone DS Patients taking verapamil or diltiazem.

Not to be given to patients w/ impaired liver function or patients who have developed jaundice or other symptoms of liver toxicity during previous treatment w/ erythromycin. Pregnancy & lactation. Ilosone 200 Concomitant use w/ CYP3A inhibitors eg, nitroimidazole antifungals. Avoid concurrent use w/ diltiazem or verapamil in patients at risk for heart irregularities or those w/ long QT manifestations. Ilosone DS Risk of hepatic dysfunction w/ or w/o jaundice. Associated w/ infrequent occurrence of cholestatic hepatitis. Reports of pseudomembranous colitis. Concomitant use w/ HMG-CoA reductase inhibitors. Reports of infantile hypertrophic pyloric stenosis in newborn infants.

Ilosone DS GI disturbances eg, abdominal cramping & discomfort, nausea, vomiting, diarrhea. Mild allergic reaction eg, urticaria & other skin rashes; serious allergic reactions including anaphylaxis. Infantile hypertrophic pyloric stenosis.

Increased serum levels & potential toxicity of theophylline. Elevated serum levels of digoxin. Increased effects of oral anticoagulants. Acute ergot toxicity w/ ergotamine or dihydroergotamine. Decreased clearance of triazolam & midazolam, which may increase pharmacologic effect of these benzodiazepines. Significantly altered metabolism of nonsedating antihistamines terfenadine & astemizole; rare cases of serious CV adverse events, including electrocardiographic QT/QTc interval prolongation, cardiac arrest, torsades de pointes, & other ventricular arrhythmias have been observed. Post-marketing reports of drug interactions w/ cisapride, resulting in QT prolongation, cardiac arrhythmias, ventricular tachycardia, ventricular fibrillation, & torsades de pointes. Ilosone 200 Risk of colchicine toxicity w/ colchicine; rhabdomyolysis w/ simvastatin, lovastatin, & atorvastatin; hypotension w/ Ca channel blockers metabolized by CYP3A4 (eg, verapamil, amlodipine, diltiazem). Decreased serum conc w/ theophylline. Hypotension, bradyarrhythmias, & lactic acidosis w/ verapamil. Co-administration w/ drugs primarily metabolized by CYP3A may be associated w/ elevations in drug conc that could increase or prolong both the therapeutic & adverse effects of the concomitant drug. Increased conc of HMG-CoA reductase inhibitors (eg, lovastatin & simvastatin). Increased systemic exposure of sildenafil. Reports of interactions w/ cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, vinblastine, & bromocriptine; hexobarbital, phenytoin, & valproate. Ilosone DS Maintenance of plasma levels may be prolonged w/ probenecid. Avoid lincomycin or clindamycin therapy in treatment of infections due to erythromycin-resistant organisms. Elevated serum conc of carbamazepine, cyclosporine, hexobarbital, phenytoin, alfentanil, disopyramide, quinidine, HMG-CoA reductase inhibitors (eg, simvastatin & lovastatin), bromocriptine, PDE5 inhibitors (eg, sildenafil, tadalafil, & vardenafil). May interfere w/ AST determinations if zone-fast violet B or diphenylhydrazine colorimetric determinations are used. Interferes w/ fluorometric determination of urinary catecholamine.

Macrolides

J01FA01 - erythromycin ; Belongs to the class of macrolides. Used in the systemic treatment of infections.

Rx